Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab
暂无分享,去创建一个
H. Yamanaka | S. Momohara | E. Inoue | N. Nishimoto | E. Tanaka | A. Nakajima | Y. Seto | E. Sato | W. Urano | D. Hoshi | K. Shidara | M. Kitahama | Y. Koseki | N. Ichikawa | A. Taniguchi
[1] A. Taniguchi,et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA , 2010, Scandinavian journal of rheumatology.
[2] R. Landewé,et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.
[3] N. Nishimoto,et al. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions , 2010, Modern rheumatology.
[4] H. Yamanaka,et al. Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan , 2009, The Journal of Rheumatology.
[5] W. Bishai,et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry , 2009, Annals of the rheumatic diseases.
[6] N. Miyasaka,et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study , 2008, Annals of the rheumatic diseases.
[7] Kazuhiko Yamamoto,et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy , 2008, Modern rheumatology.
[8] M. Genovese,et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.
[9] J. Kremer,et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.
[10] J. Smolen,et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.
[11] K. Tani,et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period , 2008, Modern rheumatology.
[12] Hyon K. Choi,et al. The risk of hospitalized infection in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.
[13] E. Inoue,et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability , 2007, Annals of the rheumatic diseases.
[14] A. Silman,et al. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .
[15] H. Yamanaka,et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[16] D. M. van der Heijde,et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.
[17] A. Taniguchi,et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA) , 2007, Modern rheumatology.
[18] J. Allison,et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.
[19] A. Silman,et al. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al , 2006, Arthritis research & therapy.
[20] E. Inoue,et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan , 2006, Annals of the rheumatic diseases.
[21] Frederick Wolfe,et al. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.
[22] Matthias Schneider,et al. Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.
[23] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[24] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[25] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[26] A. Taniguchi,et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[27] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[28] S. Gabriel,et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.
[29] F. Granath,et al. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. , 2002, The Journal of rheumatology.
[30] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[31] P. Arbogast,et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. , 2010, Rheumatology.